TORONTO, July 2, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has sold its royalty interest and milestone payment obligations in the global sales of XENPOZYME (olipudase alfa) to DRI Healthcare Trust ("DRI Healthcare"), effective June 28, 2024. All dollar amounts are in U.S. dollars, unless otherwise stated.
Read more at newswire.caHLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.